AbbVie expects $2.7 billion R&D charge in third quarter

Core Insights - AbbVie expects to incur a $2.7 billion charge in its third-quarter earnings due to in-process research and development (IPR&D) expenses [1] Financial Impact - The $2.7 billion charge is specifically related to IPR&D expenses, indicating significant investment in ongoing research projects [1]